SREBP1 promotes invasive phenotypes by upregulating CYR61/CTGF via the Hippo-YAP pathway

Chi Yu Kuo, Yuan Ching Chang, Ming Nan Chien, Jie Yang Jhuang, Yi Chiung Hsu, Shih Yuan Huang, Shih Ping Cheng

研究成果: 雜誌貢獻期刊論文同行評審

17 引文 斯高帕斯(Scopus)


Aberrant lipid metabolism provides bioenergetic, biosynthetic, and redox supplies to cancer cells. Previous studies have reported differential lipid profiling in thyroid malignancies. Sterol regulatory element-binding protein 1 (SREBP1), encoded by the SREBF1 gene, is a master regulator of cellular lipid homeostasis. The clinical and functional significance of SREBP1 in thyroid cancer is not well understood. Here, we showed that SREBP1 expression is significantly upregulated in invasive thyroid cancer than in normal thyroid tissue or benign thyroid nodules. High tumoral SREBP1 expression was associated with extrathyroidal extension, advanced disease stage, and shorter disease-specific survival in patients with differentiated thyroid cancer. SREBP1 overexpression significantly increased the oxygen consumption rate, filopodia formation, and migratory and invasive capacities of thyroid cancer cells. Knockdown of SREBF1 or treatment with an SREBP1 activation inhibitor fatostatin had the opposite effect. RNA-Seq analysis showed that modulation of SREBP1 expression was accompanied by corresponding changes in the expression of epithelial–mesenchymal transition markers and CYR61/CTGF. SREBP1-facilitated cell invasion could be abrogated by treatment with a YAP inhibitor such as verteporfin or genetic silencing of CYR61 or CTGF. In summary, SREBP1 upregulation can be used as a prognostic indicator for thyroid cancer and SREBP1 overexpression is involved in cancer invasiveness, at least partly, through upregulation of CYR61/CTGF via the Hippo-YAP pathway.

頁(從 - 到)47-58
期刊Endocrine-Related Cancer
出版狀態已出版 - 2月 2022


深入研究「SREBP1 promotes invasive phenotypes by upregulating CYR61/CTGF via the Hippo-YAP pathway」主題。共同形成了獨特的指紋。